Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma
Author:
Fischer Luise, Grieb Nora, Born Patrick, Weiss Ronald, Seiffert Sabine, Boldt Andreas, Fricke Stephan, Franz Paul, Heyn Simone, Kubasch Anne SophieORCID, Baber Ronny, Weidner Heike, Wang Song YauORCID, Bach Enrica, Hoffmann Sandra, Ussmann Jule, Kirchberg Janine, Hell Saskia, Schwind SebastianORCID, Metzeler Klaus H.ORCID, Herling Marco, Jentzsch MadlenORCID, Franke Georg-Nikolaus, Sack Ulrich, Reiche KristinORCID, Köhl Ulrike, Platzbecker UweORCID, Vucinic VladanORCID, Merz MaximilianORCID
Abstract
AbstractB-cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T cells revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM). However, data on cellular (CAR) T cell dynamics and the association with response, resistance or the occurrence of cytokine release syndrome (CRS) are limited. Therefore, we performed a comprehensive flow cytometry analysis of 27 RRMM patients treated with Idecabtagene vicleucel (Ide-cel) to assess the expansion capacity, persistence and effects on bystander cells of BCMA-targeting CAR T cells. Additionally, we addressed side effects, like cytokine release syndrome (CRS) and cytopenia. Our results show that in vivo expansion of CD8+ CAR T cells is correlated to response, however persistence is not essential for durable remission in RRMM patients. In addition, our data provide evidence, that an increased fraction of CD8+ T cells at day of leukapheresis in combination with successful lymphodepletion positively influence the outcome. We show that patients at risk for higher-grade CRS can be identified already prior to lymphodepletion. Our extensive characterization contributes to a better understanding of the dynamics and effects of BCMA-targeting CAR T cells, in order to predict the response of individual patients as well as side effects, which can be counteracted at an early stage or even prevented.
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference26 articles.
1. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45–56. https://pubmed.ncbi.nlm.nih.gov/30501490/. 2. Shiqi L, Jiasi Z, Lvzhe C, Huailong X, Liping H, Lin L, et al. Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T. Mol Ther Oncolytics. 2023;29:107–17. https://pubmed.ncbi.nlm.nih.gov/37215385/. 3. Chen PH, Lipschitz M, Weirather JL, Jacobson C, Armand P, Wright K, et al. Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy. JCI Insight. 2020;5. https://pubmed.ncbi.nlm.nih.gov/32484797/. 4. Faude S, Wei J, Muralidharan K, Xu X, Wertheim G, Paessler M, et al. Absolute lymphocyte count proliferation kinetics after CAR T-cell infusion impact response and relapse. Blood Adv. 2021;5:2128–36. https://pubmed.ncbi.nlm.nih.gov/33881465/. 5. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017;377:2531–44. https://pubmed.ncbi.nlm.nih.gov/29226797/.
|
|